In breast cancer, human epidermal growth factor receptor 2 (HER2) expression on CTCs has been assessed using CellSearch, and other investigators are using CellSearch to monitor endocrine resistance in estrogen receptor (ER)-positive, HER2-negative metastatic disease (COMETI phase II trial, NCT01701050). This evidence concerns the gene ERBB2 and breast cancer.